Durect Corp (NAS:DRRX)
$ 0.95 -0.0181 (-1.87%) Market Cap: 29.49 Mil Enterprise Value: 32.85 Mil PE Ratio: 0 PB Ratio: 24.36 GF Score: 56/100

DURECT Corp Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol Transcript

Nov 07, 2023 / 10:00PM GMT
Release Date Price: $2.58 (-0.39%)
Operator

Greetings and welcome to the Durect Corporation Phase 2b AHFIRM Topline results call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Tim Papp, Chief Financial Officer. Please go ahead.

Tim Papp
Durect Corporation - CFO

Thank you, Stacy. Good afternoon, and welcome to everyone joining us today. During this call, we will be discussing the topline data from our Phase 2b AHFIRM trial studying larsucosterol as a potential treatment for alcohol-associated hepatitis and next steps for the program. Before we begin, I encourage everyone to go to the Investor section of our corporate website to view the press release.

I would like to draw your attention to Slide 2, which contains our forward-looking statements. During the course of this call, we will make forward-looking statements regarding the results and clinical data from the AHFIRM trial, development plans for larsucosterol, expected product benefits, market potential, regulatory plans, potential regulatory approval, and the company's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot